# Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

> **NCT06644183** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jennifer R. Brown, MD, PhD** · enrollment: 64 (estimated)

## Conditions studied

- Leukemia
- Relapsed Leukemia
- Chronic Lymphocytic Leukemia
- Relapsed Cancer
- Refractory Leukemia

## Interventions

- **DRUG:** Roginolisib
- **DRUG:** Venetoclax
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06644183
- **Lead sponsor:** Jennifer R. Brown, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-19
- **Primary completion:** 2028-10-01
- **Final completion:** 2032-10-01
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06644183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06644183, "Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06644183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*